Global pharmaceutical and services company Clinigen said it traded well in the first half to the end of December and in line with the board's expectations.
Group revenues increased around 28%.
It said this was higher than the growth in gross profit due primarily to an increased level of pass through costs within the early access part of unlicensed medicines. Gross profit, viewed by the board as the best measure of top line growth, increased by around 10% compared to last year.
It said growth had been driven by a combination of a strong performance by commercial medicines and two months' contribution from Quantum Pharma plc.
Group chief executive Shaun Chilton said: 'We have delivered good growth and made strong progress against our strategic priorities, which have been enhanced by the acquisition of Quantum and IMMC.
'Our strategic priorities remain unchanged. We have and will continue to drive organic growth and search for selective acquisitions to complement our existing offering and capabilities.
We are well positioned to deliver another good year of progress.'